API Formulation Strength Reference Product Regulatory Status
Hydromorphone Immediate release capsule 1.3 - 2.6 mg Palladone® capsule Approved in the EU
Prolonged release tablet - twice daily dosing 4 - 8 - 16 - 24 mg Palladone® prolonged release capsule Approved in the EU
Prolonged release tablet - once daily dosing 4 - 8 - 16 - 32 mg Jurnista® (therapeutic equivalence demonstrated) Approved in the EU
Levomethadone Immediate release tablets 2.5 - 5 - 7.5 - 20 - 30 - 40 mg L-Polamidone tablet Approved in the EU
Methylphenidate Prolonged release tablet 18 - 27 - 36 - 54 mg "Concerta® prolonged release
tablet" Approved in the EU
Prolonged release capsule 5 - 10 - 20 - 30 - 40 - 50 - 60 mg Medikinet® XL prolonged release capsule Registration on-going
Prolonged release capsule 10 - 20 - 30 - 40 - 50 - 60 mg Equasym® prolonged release capsule Approved in the EU
Oxycodone Prolonged release tablet - once daily dosing 10 - 20 - 40 - 80 mg Develco is the originator Approved in the EU
"Oxycodone
/Naloxone" Prolonged release tablet 5/2.5 - 10/5 - 20/10 - 30/15 - 40/20 mg Targin® prolonged release tablet Approved in the EU
Prolonged release tablet 60/30 - 80/40 mg Targin® prolonged release tablet Approved in the EU
Tapentadol Prolonged release tablet - twice daily dosing 25 - 50 - 100 - 150 - 200 - 250 mg Palexia® prolonged release tablet Approved in the EU
Immediate release tablet 50 - 75 - 100 mg "Palexia® immediate release
tablet" Development on-going
Prolonged release capsules - twice daily dosing 25 - 50 - 150 - 250 mg "Palexia® prolonged release
tablet" Approved in the UK
Dexmethylphenidate "Prolonged release
TBD: Capsule/Tablet" 10 - 20 - 30 - 40 - 50 - 60 mg Focalin XR® prolonged release capsule Development on-going
Disclaimer: rights may not be available in all countries
CH